Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-19T21:18:54.671Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug attitude and subjective well-being in antipsychotic treatment monotherapy in real-world settings

Published online by Cambridge University Press:  11 April 2011

Matteo Balestrieri ,
Guido Di Sciascio ,
Miriam Isola ,
Emanuele Lomonaco ,
Elisa Maso ,
Roberto Merli ,
Salvatore Calò  and
Cesario Bellantuono
Matteo Balestrieri*
Affiliation:
Clinica di Psichiatria, Inter-University Centre for Behavioural Neurosciences, DPMSC, University of Udine, Udine
Guido Di Sciascio
Affiliation:
Azienda Universitaria Ospedale Policlinico, Bari
Miriam Isola
Affiliation:
Dipartimento di Ricerche Mediche e Morfologiche, University of Udine, Udine
Emanuele Lomonaco
Affiliation:
Struttura Complessa di Psichiatria, Dipartimento di Salute Mentale, ASL 12 Biella
Elisa Maso
Affiliation:
Clinica di Psichiatria, Inter-University Centre for Behavioural Neurosciences, DPMSC, University of Udine, Udine
Roberto Merli
Affiliation:
Struttura Complessa di Psichiatria, Dipartimento di Salute Mentale, ASL 12 Biella
Salvatore Calò
Affiliation:
Azienda Universitaria Ospedale Policlinico, Bari
Cesario Bellantuono
Affiliation:
Sezione di Psichiatria, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Ancona
*
Professor M. Balestrieri, Clinica di Psichiatria, Azienda Ospedaliero-Universitaria, p.le S. Maria della Misericordia 15, 33100 Udine (Italy). Fax: +39-0432-559188 E-mail: matteo.balestrieri@uniud.it
Get access Rights & Permissions [Opens in a new window]

Summary

Aims – To assess using two well-know scales (DAI-30 and SWN) the drug attitude and subjective well-being of patients treated with haloperidol or second-generation antipsychotics (SGA) in four different Italian communities. Methods – The sample included 145 patients taking five different antipsychotics (APs) in mono-therapy: haloperidol, clozapine, olanzapine, risperidone, quetiapine. A stepwise multiple regression analysis (SMRA) was used to analyse the contribution of different AP treatments and of other predictors to SWN and DAI-30 scores. Results – Univariate analyses showed no differences in DAI-30 and SWN scores across treatments. The SMRA showed that SWN scores were negatively correlated with the severity of the psychoses (BPRS scores), while the DAI-30 scores were negatively correlated with the severity of the psychoses and positively correlated both with the length of drug treatment and with the use of olanzapine. Conclusions – Our study does not confirm a better drug attitude in patients treated with SGA with respect to haloperidol. The only partial exception is the better performance of olanzapine over haloperidol on DAI-30, which could be due to the lower use of anticholinergic drugs during olanzapine treatment. The differences between the SWN and DAI-30 may give good reason for the use of both instruments during AP treatments.

Declaration of Interest: No grants have been received for this study. In the last two years: Matteo Balestrieri has received grants from AstraZeneca, Eli Lilly, BMS, Janssen-Cilag, Boehringer-Ingelheim, Innova-Pharma, Pfizer, Bristol, Abbott, Lundbeck; Guido Di Sciascio has received grants from AstraZeneca, Eli Lilly, BMS, Janssen-Cilag, Sanofi-Aventis, Wyeth, Boehringer- Ingelheim; Elisa Maso has received grants from Pfizer; Cesario Bellantuono has received grants from Eli Lilly, BMS, Boehringer- Ingelheim, Innova-Pharma, Italfarmaco; The other authors have not received any grants in the last two years.

Keywords

drug attitudesubjective well-beingantipsychotic drugsnaturalistic study
Type
Original Articles
Information
Epidemiology and Psychiatric Sciences , Volume 18 , Issue 2 , June 2009 , pp. 114 - 118
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Awad, A.G. & Voruganti, L. (2004). New antipsychotics, compliance, quality of life and subjective tolerability: are patients better off? Canadian Journal of Psychiatry 49, 171–176.CrossRefGoogle ScholarPubMed
Balestrieri, M., Giaroli, G., Mazzi, M. & Bellantuono, C. (2006). Performance of the Italian Version of the Subjective-Well-being Under Neuroleptics (SWN) Scale in Schizophrenic Outpatients. Pharmacopsychiatry 39, 1–4.CrossRefGoogle ScholarPubMed
Buckley, P.F., Harvey, P.D., Bowie, C.R. & Loebel, A. (2007). The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophrenia Research 94, 99–106.CrossRefGoogle ScholarPubMed
Day, J.C., Bentall, R.P., Roberts, C., Randall, F., Rogers, A., Cattell, D., Healy, D., Rae, P. & Power, Ch. (2005). Attitudes Toward Antipsychotic Medication. The Impact of Clinical Variables and Relationships With Health Professionals. Archives of General Psychiatry 62, 717–724.CrossRefGoogle ScholarPubMed
de Girolamo, G., Bellini, M., Bocchia, S. & Ruggeri, M. (1994). Brief Psychiatric Rating Scale versione 4.0 ampliata (BPRS 4.0). Epidemiologia e Psichiatria Sociale 4, 69–85.CrossRefGoogle Scholar
de Girolamo, G., Bassi, M., Neri, G., Ruggeri, M., Santone, G. & Picardi, A. (2007). The current state of mental health care in Italy: problems, perspectives, and lessons to learn. European Archives of Psychiatry and Clinical Neurosciences 257, 83–91.CrossRefGoogle ScholarPubMed
de Millas, W., Lambert, M. & Naber, D. (2006). The impact of subjective well-being under neuroleptic treatment on compliance and remission. Dialogues in Clinical Neurosciences 8, 131–136.CrossRefGoogle ScholarPubMed
Freudenreich, O., Cather, C., Eden, Evins E., Henderson, D.C. & Goff, D.C. (2004). Attitudes of schizophrenic outpatients toward psychiatric medications: relationship to clinical variables. Journal of Clinical Psychiatry 65, 1372–1376.CrossRefGoogle ScholarPubMed
Haro, J.M, Novick, D., Suarez, D. Alonso Jordi, Lepine, J.P., Ratcliffe, M. & the SOHO Study Group (2006). Remission and relapse in the outpatient care of schizophrenia. Three-year results from the Schizophrenia Outpatient Health Outcomes Study. Journal of Clinical Psychopharmacology 26, 571–578.CrossRefGoogle ScholarPubMed
Hogan, T.P., Awad, A.G. & Eastwood, R. (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminate validity. Psychological Medicine 13, 177–183.CrossRefGoogle Scholar
Karow, A., Czekalla, J., Dittmann, R.W, Schacht, A., Wagner, T., Lambert, M., Schimmelmann B.G. & Naber D. (2007). Association of subjective well-being, symptoms and side effects with compliance after 12 months of treatment in schizophrenia. Journal of Clinical Psychiatry 68, 75–80.CrossRefGoogle ScholarPubMed
Lambert, M., Naber, D., Eich, F.X., Schacht, M., Linden, M. & Schimmelmann, B.G. (2007). Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scandinavica 115,106–113.CrossRefGoogle ScholarPubMed
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J. & Hsiao, J.K., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.CrossRefGoogle ScholarPubMed
Marder, S.R. (2005). Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatrica Scandinavica 111, Suppl. 427, 43–46.CrossRefGoogle Scholar
Naber, D. (1995). A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. International Clinical Psychopharmacology 10, Suppl. 3, 133–138.Google Scholar
Naber, D. (2008). Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiologia e Psichiatria Sociale 17, 174–176.CrossRefGoogle ScholarPubMed
Naber, D., Moritz, S., Lambert, M., Pajonk, F.G., Holzbach, R., Mass, R. & Andresen, B. (2001). Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50, 79–88.CrossRefGoogle ScholarPubMed
Naber, D., Karow, A. & Lambert, M. (2005). Subjective well-being under tha neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica, Suppl. 427, 29–34.CrossRefGoogle Scholar
Phillips, G.A., van, Brunt D.L, Roychowdhury, S.M., Xu, W. & Naber, D. (2006). The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Journal of Clinical Psychiatry 67, 1397–1403.CrossRefGoogle ScholarPubMed
Rossi, A., Arduini, L., De Cataldo, S. & Stratta, P. (2001). Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI). Epidemiologia e Psichiatria Sociale 10, 107–114.CrossRefGoogle ScholarPubMed
Tiihonen, J., Wahlbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J.P.A., Volavka, J. & Haukka, J. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal 333, 224CrossRefGoogle Scholar
Voruganti, L. & Awad, A.G. (2005). Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatrica Scandinavica 111, Suppl. 427, 22–28.CrossRefGoogle Scholar
Watson, P.W., Garety, P.A., Weinman, J., Dunn, G., Bebbington, P.E., Fowler, D., Freeman, D. & Kuipers, E. (2006). Emotional dysfunction in schizophrenia spectrum psychosis: the role of illness perceptions. Psychological Medicine 36, 761–770.Google ScholarPubMed
Wehmeier, P.M., Kluge, M., Schacht, A., Helsberg, K., Schreiber, W., Schimmelmann, B.G. & Lambert, M. (2008). Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Journal of Psychiatric Research 42, 676–83.CrossRefGoogle ScholarPubMed